Search our extensive Laboratory Test Directory to find test codes, ordering recommendations, specimen stability information, Test Fact Sheets, and more.
Recommendations when to order or not order the test. May include related or preferred tests.
Use to screen for mast cell activation disorders, including systemic mastocytosis, using random urine specimens.
New York DOH Approval Status
Indicates whether a test has been approved by the New York State Department of Health.
This test is New York state approved.
Specimen Required
Patient PreparationInstructions patient must follow before/during specimen collection.
Patients taking aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) may have decreased concentrations of prostaglandin F2 alpha. If possible, discontinue for 2 weeks or 72 hours, respectively, prior to specimen collection.
CollectSpecimen type to collect. May include collection media, tubes, kits, etc.
Urine.
Specimen PreparationInstructions for specimen prep before/after collection and prior to transport.
Transfer 5 mL urine to ARUP standard transport tubes. (Min: 3 mL) Test is not performed at ARUP; separate specimens must be submitted when multiple tests are ordered.
Storage/Transport TemperaturePreferred temperatures for storage prior to and during shipping to ARUP. See Stability for additional info.
Refrigerated. Also acceptable: Frozen.
Unacceptable ConditionsCommon conditions under which a specimen will be rejected.
RemarksAdditional specimen collection, transport, or test submission information.
StabilityAcceptable times/temperatures for specimens. Times include storage and transport time to ARUP.
Quantitative Liquid Chromatography-Tandem Mass Spectrometry /Colorimetry
Performed
Days of the week the test is performed.
Varies
Reported
Expected turnaround time for a result, beginning when ARUP has received the specimen.
6-11 days
Reference Interval
Normal range/expected value(s) for a specific disease state. May also include abnormal ranges.
By Report
Interpretive Data
May include disease information, patient result explanation, recommendations, or details of testing.
Compliance Category
Performed by non-ARUP Laboratory
Note
Additional information related to the test.
Elevated levels of 2,3-dinor-11beta-prostaglandin F2 alpha (2,3 BPG) in urine are not specific for systemic mast cell disease and may be found in patients with angioedema, diffuse urticaria, or myeloproliferative diseases in the absence of diffuse mast cell proliferation.
The American Medical Association Current Procedural Terminology (CPT) codes published in ARUP's Laboratory Test Directory are provided for informational purposes only. The codes reflect our interpretation of CPT coding requirements based upon AMA guidelines published annually. CPT codes are provided only as guidance to assist clients with billing. ARUP strongly recommends that clients confirm CPT codes with their Medicare administrative contractor, as requirements may differ. CPT coding is the sole responsibility of the billing party. ARUP Laboratories assumes no responsibility for billing errors due to reliance on the CPT codes published.
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
Aliases
Other names that describe the test. Synonyms.
11 Beta-Prostaglandin F2 Alpha
11BPG
2, 3 11 Beta-Prostaglandin F2 Alpha
23BPG
BPG2
Mastocytosis
Prostaglandin
2,3 Dinor-11Beta-Prostaglandin F2 Alpha, Random Urine
Connect Sign In
